Table 1.
Baseline Characteristics of Study Participants.
| Characteristic | No. (%) | |
|---|---|---|
| Patients (n = 116) | Controls (n = 35) | |
| Age, median (range) | 68 (24–91) | 60 (43–79) |
| Sex | ||
| Male | 41 (35.3) | 12 (34.3) |
| Female | 75 (64.7) | 23 (65.7) |
| Solid Tumours | 76 (65.5) | N/A |
| Breast | 26 (22.4) | |
| Gastrointestinal | 21 (18.1) | |
| Lung | 12 (10.3) | |
| Melanoma | 7 (6.0) | |
| Genitourinary | 5 (4.3) | |
| Gynecologic | 3 (2.6) | |
| Other | 2 (1.7) | |
| Hematologic Malignancy | 40 (34.5) | |
| Lymphoma | 21 (18.1) | |
| Leukemia | 6 (5.2) | |
| Multiple myeloma | 5 (4.4) | |
| Other | 8 (6.9) | |
| Cancer treatment within 3 months of participation | 89 (76.7) | N/A |
| Vaccine Received | ||
| Pfizer-NBiotech (two doses) | 84 (72.4) | 12 (34.3) |
| AstraZeneca (two doses) | 11 (9.5) | 4 (11.4) |
| Moderna (two doses) | 10 (8.6) | 1 (2.9) |
| Mixed doses | 11 (9.5) | 18 (51.4) |
| Days between 1st and 2nd dose, mean (SD) | 50 (±24) | 66 (±14) * |
| Days between 2nd dose and blood collection, mean (SD) | 44 (±27) | 53 (±17) |
* Further analysis discussed in 3.5.